Clinical trial · Observational
The Methylation Phenotype Screening and Determination Mode Study of Liver Cancer Prognosis Related Gene
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Recurrence and metastasis are the main factors affecting the prognosis of liver cancer after curative resection. Establishing an effective prognostic evaluation method is able to not only assess patients' prognosis but also guide the treatment. At the same time, it helps us to gain knowledge of the mechanism underlying recurrence and metastasis of liver cancer and to provide the basis for the search for new effective intervention method. In order to establish an effective prognostic evaluation method, we select liver cancer patients undergoing curative resection in our hospital. We plan to employ various technologies such as gene chip, methylation chip and flow cytometry to carry out comprehensive researches on liver cancer cell genetics, epigenetics, stem cells and tumor microenvironment changes. By analyzing clinical information including pathological features, patients' response to treatment, relapse, metastasis and survival, we aim to obtain the important factors affecting liver cancer prognosis, survival, recurrence and metastasis in order to be able to find and establish the effective prognostic evaluation method.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma; | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Radical Hepatic Resection; | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- liver cancer, Radical hepatic resection
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- 2015
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with radical hepatectomy in Eastern Hepatobiliary Surgery Hospital; 2. Hepatocellular carcinoma confirmed pathologically; 3. The liver function is Child-Pugh A, as well as the Child-Pugh B achieved to A after treatment; 4. The HAI score of cirrhosis \<12 Exclusion Criteria: 1. Patients with apparent cardiac, pulmonary, cerebric and renal dysfunction,which may affect the treatment of liver cancer. 2. Patients with other diseases which may affect the treatment mentioned here. 3. Patients with medical history of other malignant tumors.
References
Publications (0)
Data not yet available